FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Accelerated Approval On- and Off-Ramp Approaches

[ Price : $8.95]

Staff in the FDA Oncology Center of Excellence say ways must be found to improve studies leading to accelerated approval to shorte...

Panel Votes Down Spectrum Lung Cancer Drug

[ Price : $8.95]

FDAs Oncologic Drugs Advisory Committee votes 9-4 against recommending accelerated approval for Spectrum Pharmaceuticals Pozenveo ...

Medtronic Cardiac Monitor Gets Expanded Use

[ Price : $8.95]

FDA clears a Medtronic 510(k) for its LINQ II Insertable Cardiac Monitor system for expanded use in pediatric patients over the ag...

DoJ Increasing Corporate Enforcement

[ Price : $8.95]

Former U.S. Attorney Gregory Brower discusses four takeaways from a recent Department of Justice memo on increased corporate enfor...

Guide on Drug Covered Product Authorizations

[ Price : $8.95]

FDA posts a draft guidance entitled How to Obtain a Covered Product Authorization for generic drug developers having trouble getti...

Rx NIX Not Withdrawn Due to Safety/Efficacy

[ Price : $8.95]

Federal Register notice: FDA determines that GlaxoSmithKlines prescription-only NIX (permethrin) 1% topical creme rinse was not wi...

5 Observations in Cipla FDA-483

[ Price : $8.95]

FDA releases a form FDA-483 with five observations from an inspection at the Cipla drug manufacturing facility in Goa, India.

OIG Identifies FDA Emergency Use Authorization Issues

[ Price : $8.95]

FDA concurs with six recommendations made by the HHS Inspector General to improve the EUA process for tests in a future pandemic.

FDA Approves Pedmark for Cisplatin Ototoxicity

[ Price : $8.95]

FDA approves Fennec Pharmaceuticals Pedmark to treat cisplatin-associated ototoxicity in pediatric patients.

Panel to Discuss Zejula Supplemental NDA

[ Price : $8.95]

Federal Register notice: FDA announces an 11/22 Oncologic Drugs Advisory Committee meeting to discuss a GlaxoSmithKline supplement...